Recently Activated Protocols

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Physician Summary: ≥ age 18, Central HER2 Testing: RT +/- Trastuzumab

40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanopartical Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First -Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Physician Summary: ≥ age 18, Stage IIIB or IV,: Paclitaxel or Nab-Paclitaxel or Ixabepilone w/Bevacizumab

N0723: MARVEL - Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation Study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) randomized to Pemetrexed Versus Erlotinib

Physician Summary: ≥ age 18, Recurrent or Disease Progression, Central Review of Tissue Required: Erlotinib vs Pemetrexed

LUN 179: Phase II Trial of Ixabepilone and Carboplatin with or without Bevacizumab in Patients with Previously Untreated Advanced Non Small-Cell Lung Cancer

Physician Summary: ≥ age 18, Prev. Untreated, Stage III or IV: Ixabepilone and Carboplatin +/- Bevacizumab

N07C2: The Use of Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Physician Summary: ≥ age 18, Tx must be curative: Wisconsin Ginseng